
|Articles|June 1, 2003
- Psychiatric Times Vol 20 No 6
- Volume 20
- Issue 6
After the Famous Poet
Poetry of the Times
Advertisement
After the Famous Poet
recites a poem
that ends with "a purple stain,"
she recalls how she went to war
with another famous poet
about whether it is proper
to end a poem with a color.
And I envy the famous poet
for living in a world
where battles over colorful words
can feel like life and death.
For years ago I chose a world
where colorful words
like "green meconium stain"
or "peau d'orange"
describe deformity beyond metaphor,
a war where flesh is cut and colored
to let us read the body's text,
our precise choice of words
as brilliant and final
as the last line of any poem.
Articles in this issue
over 23 years ago
Confidentiality Under Fireover 23 years ago
Stigma Continues in Hollywoodover 23 years ago
The Art of the Unconsciousover 23 years ago
Psychiatrists Strive to Assure Patients' Safetyover 23 years ago
Conference Probes Pathology of Self-Awarenessover 23 years ago
Music Therapy With Emotionally Disturbed Childrenover 23 years ago
The Assessment of Danger in Everyday Practiceover 23 years ago
The Other Side of the Storyover 23 years ago
Using Creativity to Explore in PsychotherapyAdvertisement
Related to this article

Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.

Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.

Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.

Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.

Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.

The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.

Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Shelves Fast-Track Drug Review Initiative
2
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
3
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
4
Reviewing Roluperidone as Treatment for Negative Symptoms in Schizophrenia
5

